Skip to main content
LON:NCYT

Novacyt Competitors

GBX 402.50
+14.30 (+3.68 %)
(As of 05/13/2021 05:07 PM ET)
Add
Compare
Today's Range
366.40
407.21
50-Day Range
370.50
727
52-Week Range
202.75
1,276
Volume1.03 million shs
Average Volume942,158 shs
Market Capitalization£284.27 million
P/E Ratio7.82
Dividend YieldN/A
BetaN/A

Competitors

Novacyt (LON:NCYT) Vs. PRTC, OXB, ERGO, SLN, ARIX, and ORPH

Should you be buying NCYT stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Novacyt, including PureTech Health (PRTC), Oxford Biomedica (OXB), Ergomed (ERGO), Silence Therapeutics (SLN), Arix Bioscience (ARIX), and Open Orphan (ORPH).

PureTech Health (LON:PRTC) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares PureTech Health and Novacyt's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PureTech Health£11.77 million87.58N/AGBX 1.40257.50
Novacyt£78.23 million3.63N/AGBX 51.507.82

Novacyt is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PureTech Health and Novacyt's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PureTech HealthN/AN/AN/A
NovacytN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings for PureTech Health and Novacyt, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PureTech Health00403.00
Novacyt02002.00

PureTech Health presently has a consensus target price of GBX 496.25, suggesting a potential upside of 37.66%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts plainly believe PureTech Health is more favorable than Novacyt.

Summary

PureTech Health beats Novacyt on 5 of the 7 factors compared between the two stocks.

Oxford Biomedica (LON:OXB) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current recommendations for Oxford Biomedica and Novacyt, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oxford Biomedica01202.67
Novacyt02002.00

Oxford Biomedica presently has a consensus target price of GBX 1,003.33, suggesting a potential downside of 1.05%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, equities research analysts clearly believe Oxford Biomedica is more favorable than Novacyt.

Profitability

This table compares Oxford Biomedica and Novacyt's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oxford BiomedicaN/AN/AN/A
NovacytN/AN/AN/A

Earnings & Valuation

This table compares Oxford Biomedica and Novacyt's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Biomedica£87.73 million9.52N/AGBX (7.80)-130.00
Novacyt£78.23 million3.63N/AGBX 51.507.82

Oxford Biomedica is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

Summary

Oxford Biomedica beats Novacyt on 5 of the 7 factors compared between the two stocks.

Novacyt (LON:NCYT) and Ergomed (LON:ERGO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Valuation and Earnings

This table compares Novacyt and Ergomed's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£78.23 million3.63N/AGBX 51.507.82
Ergomed£86.39 million6.72N/AGBX 19.2061.98

Novacyt is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Novacyt and Ergomed, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novacyt02002.00
Ergomed0000N/A

Profitability

This table compares Novacyt and Ergomed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovacytN/AN/AN/A
ErgomedN/AN/AN/A

Summary

Ergomed beats Novacyt on 3 of the 4 factors compared between the two stocks.

Novacyt (LON:NCYT) and Silence Therapeutics (LON:SLN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Profitability

This table compares Novacyt and Silence Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovacytN/AN/AN/A
Silence TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Novacyt and Silence Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novacyt02002.00
Silence Therapeutics02002.00

Silence Therapeutics has a consensus price target of GBX 605, suggesting a potential downside of 0.17%. Given Silence Therapeutics' higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than Novacyt.

Valuation and Earnings

This table compares Novacyt and Silence Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£78.23 million3.63N/AGBX 51.507.82
Silence Therapeutics£5.48 million98.88N/AGBX (39.80)-15.23

Silence Therapeutics is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

Summary

Novacyt beats Silence Therapeutics on 3 of the 5 factors compared between the two stocks.

Novacyt (LON:NCYT) and Arix Bioscience (LON:ARIX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Novacyt and Arix Bioscience, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novacyt02002.00
Arix Bioscience01002.00

Profitability

This table compares Novacyt and Arix Bioscience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NovacytN/AN/AN/A
Arix BioscienceN/AN/AN/A

Earnings & Valuation

This table compares Novacyt and Arix Bioscience's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£78.23 million3.63N/AGBX 51.507.82
Arix Bioscience£135.77 million1.81N/AGBX 88.702.07

Arix Bioscience is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

Open Orphan (LON:ORPH) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Open Orphan and Novacyt, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Open Orphan0000N/A
Novacyt02002.00

Given Open Orphan's higher probable upside, analysts plainly believe Open Orphan is more favorable than Novacyt.

Earnings and Valuation

This table compares Open Orphan and Novacyt's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Open Orphan£10.57 million22.13N/AGBX (3.20)-10.92
Novacyt£78.23 million3.63N/AGBX 51.507.82

Open Orphan is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Open Orphan and Novacyt's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Open OrphanN/AN/AN/A
NovacytN/AN/AN/A

Summary

Novacyt beats Open Orphan on 3 of the 5 factors compared between the two stocks.


Novacyt Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
PureTech Health logo
PRTC
PureTech Health
1.5$360.50+0.1%£1.03 billion£11.77 million257.50News Coverage
Gap Down
Oxford Biomedica logo
OXB
Oxford Biomedica
0.8$1,014.00+0.4%£838.88 million£87.73 million-130.00
Ergomed logo
ERGO
Ergomed
0.6$1,190.00+0.4%£582.56 million£86.39 million61.98
Silence Therapeutics logo
SLN
Silence Therapeutics
0.7$606.00+1.3%£548.91 million£5.48 million-15.23Gap Up
ARIX
Arix Bioscience
0.8$184.00+0.5%£246.69 million£135.77 million2.07
ORPH
Open Orphan
0.0$34.95+5.3%£246.34 million£10.57 million-10.92
Bioventix logo
BVXP
Bioventix
0.8$4,160.00+0.2%£216.17 million£10.38 million31.71
Synairgen logo
SNG
Synairgen
1.1$100.10+0.8%£201.71 million£79,000.00-19.63Analyst Report
News Coverage
Gap Up
Redx Pharma logo
REDX
Redx Pharma
0.6$62.50+4.0%£178.03 million£5.69 million-11.57
DDDD
4D pharma
0.6$96.00+1.0%£171.29 million£690,000.00-5.03Gap Down
Scancell logo
SCLP
Scancell
0.6$20.55+2.2%£171.20 millionN/A-14.68
Faron Pharmaceuticals Oy logo
FARN
Faron Pharmaceuticals Oy
0.6$327.50+1.5%£167.77 million£2.12 million-10.17
Tiziana Life Sciences logo
TILS
Tiziana Life Sciences
0.4$72.50+2.8%£144.99 millionN/A-13.18
Mereo BioPharma Group plc (MPH.L) logo
MPH
Mereo BioPharma Group plc (MPH.L)
0.6$26.50+1.9%£138.87 millionN/A-0.21Gap Down
Circassia Group logo
CIR
Circassia Group
0.9$33.50+2.2%£136.96 million£23.90 million-3.81
VSN
Verseon
0.5$74.00+2.0%£127.41 millionN/A-5.17Gap Up
ANIC
Agronomics
0.5$24.85+3.4%£124.72 million£1.05 million-124.25High Trading Volume
News Coverage
ETX
e-therapeutics
0.4$26.70+7.9%£121.18 million£305,000.00-26.70Upcoming Earnings
News Coverage
Gap Down
Verona Pharma plc (VRP.L) logo
VRP
Verona Pharma plc (VRP.L)
0.5$55.00+5.5%£108.11 millionN/A-1.68Gap Up
C4XD
C4X Discovery
0.6$41.00+2.4%£95.07 million£7.06 million-7.74
SBTX
SkinBioTherapeutics
0.4$59.00+8.5%£92.50 millionN/A-59.00High Trading Volume
Destiny Pharma logo
DEST
Destiny Pharma
0.8$140.00+2.1%£85.60 million£12,450.00-11.67
ReNeuron Group logo
RENE
ReNeuron Group
0.6$129.90+1.6%£75.05 million£112,000.00-2.83News Coverage
OBD
Oxford BioDynamics
0.5$73.00+3.2%£69.70 million£456,000.00-15.53Gap Down
Tissue Regenix Group logo
TRX
Tissue Regenix Group
0.9$0.70+2.7%£47.83 million£12.83 million-3.50Insider Buying
Gap Up
IXICO logo
IXI
IXICO
0.9$89.20+4.3%£44.61 million£9.53 million44.60
OKYO
OKYO Pharma
0.5$6.50+0.8%£44.07 millionN/A-65.00
HVO
Hvivo
0.5$16.50+5.3%£43.61 million£12.09 million-0.83
OptiBiotix Health logo
OPTI
OptiBiotix Health
0.8$47.50+3.2%£43.09 million£687,584.00-20.65News Coverage
Gap Down
4BB
4basebio UK Societas
0.3$370.00+1.4%£42.49 millionN/A0.00High Trading Volume
FAB
Fusion Antibodies
0.5$148.00+1.4%£38.22 million£4.05 million-49.33News Coverage
RUA
Rua Life Sciences
0.0$138.00+1.1%£30.28 million£835,000.00-16.83Analyst Report
News Coverage
COS
Collagen Solutions plc (COS.L)
0.6$6.63+0.0%£28.43 million£4.01 million-8.28
AOR
AorTech International
0.5$123.50+2.4%£21.85 million£539,000.00-33.38
ImmuPharma logo
IMM
ImmuPharma
0.6$8.82+4.7%£21.02 million£126,667.00-2.59
Midatech Pharma logo
MTPH
Midatech Pharma
0.7$27.00+1.9%£17.43 million£390,000.00-0.29Upcoming Earnings
NFX
Nuformix
0.5$2.31+3.9%£14.20 million£195,550.00-11.55
RLM
Realm Therapeutics
0.7$11.50+0.0%£13.41 million£501,919.00-0.66
ValiRx logo
VAL
ValiRx
0.7$19.70+1.5%£13.01 millionN/A-5.18
HEMO
Hemogenyx Pharmaceuticals
0.4$2.18+6.9%£11.49 millionN/A-5.44
OVB
Ovoca Bio
0.7$10.55+4.3%£9.29 millionN/A-2.85
NSCI
NetScientific
0.5$54.00+1.9%£7.96 million£394,000.00-5.00News Coverage
Horizon Discovery Group plc (HZD.L) logo
HZD
Horizon Discovery Group plc (HZD.L)
0.8$4.13+2.9%£6.78 million£54.63 million-0.75Gap Up
PYC
Physiomics
0.4$6.17+2.8%£5.84 million£884,649.00-61.70
Motif Bio logo
MTFB
Motif Bio
0.6$0.50+0.0%£3.28 millionN/A-0.25
SALV
SalvaRx Group
0.9$4.50+0.0%£1.65 million£64.50 million0.03Gap Up
PEBI
Port Erin Biopharma Investments
0.6$4.50+100.0%£1.04 million£28,300.00-6.43Gap Up
Abzena logo
ABZA
Abzena
0.6$15.75+0.0%£0.00N/A0.00
Vernalis logo
VER
Vernalis
0.7$6.17+0.0%£0.00N/A0.00
This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.